Dengue virus (DENV) is a mosquito-borne virus that belongs to the Flaviviridae family. It is responsible for causing dengue fever, a disease that affects millions of people worldwide, particularly in tropical and subtropical regions. The virus has four genetically distinct serotypes: DENV-1, DENV-2, DENV-3, and DENV-4 . Each serotype can cause a range of symptoms from mild febrile illness to severe dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) .
DENV-4 is one of the four serotypes of the dengue virus. It has been associated with outbreaks in various parts of the world, including Southeast Asia, the Pacific Islands, and the Americas . The emergence of new genotypes within DENV-4 has led to increased severity of the disease in some regions . Understanding the molecular characteristics of DENV-4 is crucial for developing effective diagnostic tools and vaccines.
Recombinant technology involves the use of genetic engineering to produce viral proteins in various host systems. This approach is widely used in the development of vaccines and diagnostic tools. Recombinant dengue virus proteins can be produced in different expression systems, including bacterial, yeast, mammalian, and insect cells .
Insect cells are commonly used for the production of recombinant proteins due to their ability to perform post-translational modifications similar to those in mammalian cells. The baculovirus expression vector system (BEVS) is a popular method for producing recombinant proteins in insect cells . This system involves the use of baculovirus to infect insect cells, leading to high-level expression of the desired protein.
The production of DENV-4 recombinant proteins in insect cells involves several steps:
Recombinant DENV-4 proteins produced in insect cells have several applications: